Leslie E. Huye

Mutational analysis of all conserved basic amino acids in RAG-1 reveals catalytic, step arrest, and joining-deficient mutants in the V(D)J recombinase.

The V(D)J recombinase efficiently cleaves and transposes signal joints.

Contribution of Vh gene replacement to the primary B cell repertoire.

Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit.

Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling.

Interferon regulatory factor 7 is negatively regulated by the Epstein-Barr virus immediate-early gene, BZLF-1.

Interferon regulatory factor 5 represses expression of the Epstein-Barr virus oncoprotein LMP1: braking of the IRF7/LMP1 regulatory circuit.

Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination.

Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).

Designing T cells for cancer immunotherapy.

T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.

Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.

Hyperactive piggyBac gene transfer in human cells and in vivo.

Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.